Sanofi India Limited has received an order from the State Tax Officer, Tiruvallur Assessment Circle, dropping a Goods and Services Tax (GST) demand of ₹1.07 crore for FY23. The ruling concludes ongoing proceedings with no additional dues or penalties remaining for the company.

The order, received on September 21, 2026, accepts the company’s submissions regarding anomalies found in GSTR filings for the fiscal year 2022-23. The tax authority initiated these proceedings under Section 73 of the TNGST/CGST Act, 2017, citing significant differences in the filed returns.

Regulatory Context

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The order specifically addresses the tax demand along with associated interest and penalty, which have now been waived.

Operational Impact

The company stated that the resolution of this matter has no material impact on its financial, operational, or other activities. With the acceptance of its submissions, Sanofi India Limited has closed this specific regulatory chapter for the referenced period.

Sanofi India Limited disclosed a proposed acquisition of up to 3.5 million equity shares by its promoter group entity, Sanofi Healthcare India Private Limited, from fellow promoter Hoechst GmbH.

The transaction, valued at a price not exceeding the regulatory limits under SEBI’s Takeover Regulations, represents an inter-se transfer within the promoter group. The acquirer is exempt from making an open offer pursuant to Regulation 10(1)(a)(iii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Transaction Details

The proposed acquisition is scheduled to be undertaken on or after September 24, 2026. Sanofi Healthcare India Private Limited will acquire the shares from Hoechst GmbH, reducing the latter’s stake while establishing a new holding for the former.

The volume-weighted average market price of Sanofi India shares over the 60 trading days preceding the notice issuance was ₹3,228.06 per share. The acquirer confirmed that the acquisition price would not exceed 25% above this computed benchmark.

What the Numbers Show

The restructuring consolidates promoter holdings through a significant shift in ownership structure. Hoechst GmbH’s stake will decrease by 15.20 percentage points, dropping from 60.38% to 45.18%, while Sanofi Healthcare India Private Limited moves from nil to a 15.20% holding. This internal realignment does not alter the total promoter group shareholding but changes the specific entities controlling the voting rights.